Arca
Skip to content
Tools
Tools

Endometrial cancer

Drug research and approvals for endometrial cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 349 studies of endometrial cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 46 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 349
  • Trials authorized in Canada: 46
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 349 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 2

Phase 3 12 of 31

Phase 2 12 of 89

Phase 1 or earlier 12 of 33

How its trials ended

1,118 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 170 whose ending is known, 25% met their primary endpoint, 13% missed it and 62% stopped early.

  • Ongoing44640%
  • Completed, result not reported35632%
  • Status unknown14613%
  • Stopped: other or unclear585%
  • Met its primary endpoint424%
  • Stopped: enrollment or feasibility252%
  • Missed its primary endpoint222%
  • Stopped: sponsor or business decision121%
  • Stopped: lack of efficacy61%
  • Stopped: funding5<1%

Trials authorized in Canada

The 10 newest of 46; search them all in Canada trials
Sep 23, 2026A phase 3, open-label, multicenter, randomized study of raludotatug deruxtecan (MK-5909, r-dxd) with or without bevacizumab versus standard-of-care…Raludotatug deruxtecan (MK-5909) / Avastin (bevacizumab) / Mvasi (bevacizumab)Merck & Co. (MSD)Pending
Sep 11, 2026An open-label, multicenter, 2-part study: a phase 1b dose selection followed by a randomized phase 3 to evaluate the pharmacokinetics, efficacy, and safety of…Jemperli / Dostarlimab sc / ALT-BB4GSKPending
Jul 28, 2026A randomized, open-label, multicenter, phase 3 study to investigate GSK5733584 in combination with immune checkpoint inhibition for maintenance treatment of…Mocertatug rezetecan (GSK5733584) / Keytruda / JemperliGSKOngoing
Jul 27, 2026An interventional phase 3, open label, randomized study to evaluate efficacy and safety of PF-08634404 in combination with chemotherapy versus pembrolizumab in…PF-08634404 (SSGJ-707) / Keytruda / Carboplatin / Paclitaxel / DocetaxelPfizerOngoing
Mar 18, 2026Weight-loss drug for fertility-sparing treatment of atypical hyperplasia and low-grade cancer of the endometrium (we-fierce)WegovyDr. Sarah E. Ferguson, University Health NetworkOngoing
Dec 18, 2025A randomized, open-label, multicenter, phase 3 study to investigate GSK5733584 compared with chemotherapy in participants with recurrent endometrial cancerGSK5733584 / Paclitaxel / DoxorubicinGSKOngoing
Dec 5, 2025A phase 3 randomized, open-label study of rinatabart sesutecan (rina-s) versus treatment of investigator’s choice (IC) in patients with endometrial cancer…Rinatabart sesutecan (rina-s) (PRO1184) (GEN1184) / Paclitaxel / DoxorubicinGenmabOngoing
Sep 12, 2025A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan versus standard of care chemotherapy with or without radiotherapy as adjuvant…EnhertuDaiichi SankyoOngoing
Jul 28, 2025Weight-loss drug for fertility-sparing treatment of atypical hyperplasia and low-grade cancer of the endometrium (we-fierce)Levonorgestrel / TirzepatideUniversity Health NetworkClosed
Jul 4, 2025A phase III, randomized, open-label, multicenter, global study of puxitatug samrotecan (AZD8205) monotherapy versus physician's choice of chemotherapy in…AZD8205AstraZeneca PharmaceuticalsOngoing

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Jan 12, 2011CridanimodTreatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.Xenetic Biosciences, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Apr 21, 2021JemperliDostarlimabGlaxoSmithKline Trading Services LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.